IL6 and polymyalgia rheumatica: To further validate our genetic instrument against clinical outcomes, we tested, as positive controls, associations with polymyalgia rheumatica and rheumatoid arthritis, for which pharmacological IL-6 signaling inhibition has been proven efficacious in phase 3 trials37,38.